Revival in domestic business should also help overall revenue growth.
Short sellers may capitalise on the weak sentiment owing to the dispute between co-founders Rana Kapoor and Madhu Kapur.
Given its track record, cautious analysts are monitoring progress on these fronts.
The combined market capitalisation of the two listed companies of the Sahara group whose assets have been ordered frozen by the Securities and Exchnage Board of India is just Rs 230 crore.
Interview with CMD, Motilal Oswal Financial Services
This time its international business is in the limelight.
While slowing earnings growth has seen the ratio fall to 64%, more reforms, lower interest rates could improve the equation.
Analysts believe that investors will remain cautious this week ahead of results of HDFC and Infosys.
Some state-run banks made 10,000-13,000 per cent gains on their holdings in the Multi Commodity Exchange (MCX) after the latter commodity bourse made an impressive listing on Friday.
While domestic sales in the second quarter are expected to be weak for major players, Lupin is likely to outperform the pharma sector on the back of a growing chronic portfolio.
Severe price cuts help multinationals ramp up growth, gain market share.
Aggressive smaller players are serving a bitter pill to the big boys in the pharmaceutical sector.
More pain likely, say analysts, with gloomy demand scenario and slowing economy.
Footfalls increase at retail outlets and auto dealers, but conversions fall.
India's weight in the emerging market portfolios of foreign institutional investors (FIIs) has risen by about 100 basis points in June to 7.96 per cent as compared to May.
Importantly, after the interest rate rises by the Reserve Bank of India (RBI) in the recent past, there is a high probability of corporate India getting hit on profits.
Companies together have lost about Rs 20,000 crore (Rs 200 billion) in market value since the arrest of former telecom minister, A Raja, leading to historically low valuations.
India's largest pharma companies by market capitalisation Sun Pharma, Dr Reddy's and Cipla have seen their share prices drop 5-20 per cent over the last two weeks on results that were below Street expectations.
Management quality and issue price are key concerns for investors; over 60 per cent of the issues this financial year are trading below issue price.
The BSE Realty index fell 11 per cent over the last month and eight per cent over the week as real estate companies reported margin pressures in the September quarter.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances